`Pharmaceutical
`Solids
`
`edited by
`Harry G. Brittain
`
`Discovery Laboratories, Inc.
`Milford, New Jersey
`
`NEw YORK ¯ BASEL
`
`Lupin Ex. 1043 (Page 1 of 33)
`
`
`
`ISBN: 0-8247-0237-9
`
`This book is printed on acid-free paper.
`
`Headquarters
`Marcel Dekker, lnc,
`270 Madison Avenue, New York, NY 10016
`tel: 212-696-9000: fax: 212-685-4540
`
`Ea~rn HemL~phere Distribution
`Marcel Dekker AG
`Hutgasm 4, Posffach 812, CH-a,001 Basel, Switzerland
`tel: 44-61-261-8482: fax: 44-61-261-8996
`
`World Wide Web
`http:ttwww.deLker.com
`
`The publisher offers discounts on this book when ordered in bulk quantities. For more
`information, write to Special Sales/Professional Marketing at the headquarters address
`above.
`
`Copyright © 1999 by Marcel Dekker, Inc. All RighLs Reserved.
`
`Neither this book nor any part may be reproduced or transmitted in any form or by
`any means, elcctronic or mechanical, including photocopying, microlilming, and re-
`cording, or by any information storage and retrieval system, without permission in
`wriling from the publisher.
`
`Current printing (last digit):
`10 9 8 7 6 5 4 3 2 1
`
`PRINTED IN THE UNITED STATF2; OF AMERICA
`
`Lupin Ex. 1043 (Page 2 of 33)
`
`
`
`This material may be protected by Copyright law (Title 17 U,S, Code)
`
`8
`
`Effects of Pharmaceutical
`Processing on Drug Polymorphs
`and Solvates
`
`Harry G. Brittain
`
`Discovery Laboratories, Inc.
`Milford, New jersey
`
`Eugene F, Fiese
`
`Pfizer Central Research
`Groton, Connecticut
`
`I. INTRODUCTION
`
`II. PRODUCTION AND STORAGE OF BULK DRUG
`SUBSTANCE
`
`lit. EFFECTS OF PARTICLE SIZE REDUCTION
`
`IV. EFFECTS DUE TO GRANULATION
`
`V. EFFECTS DUE TO DRYING
`A. Changes in Crystalline Form Accompanying lhe Spray-
`Drying Process
`
`332
`
`333
`
`3.34
`
`339
`
`341
`
`343
`
`331
`
`Lupin Ex. 1043 (Page 3 of 33)
`
`
`
`332
`
`Vl.
`
`B. Changes in the Crystalline State of Lyophilized
`Products
`
`EFFECTS DUE TO COMPRF.,SSION
`A. Changes in Crystal Form Effected by Compaction
`B, Effects on Tablet Properties Associated with the Use of
`Different Crystal Forms
`
`VII, SUMMARY
`
`REFERENCES
`
`!
`INTRODUCTION
`
`I.
`
`Brlttain and Flese
`
`345
`
`348
`348
`
`353
`
`356
`
`358
`
`in the previous chapters, the structural origin, energefics, and thermo-
`dynamics of polymorphs and solvates have been largely described for
`pure chemical entities. In most of the studies reported, the compounds
`were intentionally converted among various polymorphic form.~ for the
`purpose of study, in the present chapter, we will discuss the uninten-
`tional conversion of polymorphs and the desolvation of hydrates upon
`exposure to the energetics of pharmaceutical processing. Environments
`as harsh as 80°C and 100% RH for up to 6 h are not unusual during the
`routine manufacture of dosage forms. As previously noted, the various
`crystalline polymorphs frequently differ in their heats of fusion by as
`little as 1 kcal/mol, with the transition temperature being well below
`the boiling point of water. In the case of hydrates, removal of water
`from the crystal lattice requires more energy but is very much depen-
`dent on the t~mperature and humidity history of the sample.
`In this chapter we will discuss the effects of pharmaceutical pro-
`cessing upon the crystalline state of polymorphic and solvate systems.
`Given the degree of attention lavished on drug substances that is re-
`quired by solid-state pharmaceutical [1] and regulatory [2] concerns,
`it is only logical thal an equivalent amount ()f attention be paid to pro-
`cessing issues. A variety of phase conversions are possible upon expo-
`sure to the energetic steps of bulk material storage, drying, milling,
`wet granulation, oven drying, and compaction. In this setting, an envi-
`ronrnenl as harsh as 80°C and 100% RH for up to 12 h is not unusual,
`
`Lupin Ex. 1043 (Page 4 of 33)
`
`
`
`Effects of Pharmaceutical Processing
`
`333
`
`and the mobility of water among the various components must be con-
`sidered.
`
`II. PRODUCTION AND STORAGE OF BULK DRUG
`SUBSTANCE
`
`The first processing opportunity to effect a change in polymorphic form
`or solvate naturc is with the final crystallization step in the synthesis
`of the bulk d~g substance. Crystallization is thought to occur by first
`forming hydrogen-bonded aggregates in the solution state, followed by
`the buildup of molecules to produce a crystal nucleus. A number of
`parameters are known to affect the crystallization process, including
`solvent composition and polarity, drug concentration and degree of su-
`persaturation, temperature and cooling rate during the crystallization
`process, presence of seed crystals and/or nucleation sites, additives that
`influence crystal habit or add strain to the crystal lattice, agitation, pH,
`and the presence of a salt-forming molecule. It is evident that ample
`opportunity exists for the appearance of a polymorphic change when
`a process is scaled up, or moved to a new site, or run by a new operator.
`Since the discovery chemist would have been able to make gram
`quantities of a quasi-crystalline drug substance, logic holds that the
`process chemist should be able to make kilograms of the same sub-
`stance in a GMP manufacturing setting. While Mother Nature and equi-
`librium may have bcen fooled at the bench-top (where reaction steps
`are short and yield is improved through the use of anti solvents), longer
`processing times and improvements in putty usually mean that thermo-
`dynamic equilibrium will be achieved for the first time at the scale-up
`stage. On the other hand, the need for high yield frequendy is the chief
`motivating force carly in a development program, so even the first
`scale-up phase often fails to produce the thermodynamically preferred
`polymorph. Eventually, either at the first seale-up site or when the pro-
`cess is moved to a new site, the thermodynamically preferred form will
`appear. This observation has been attributed to Gay-Lussac, who noted
`that unstable forms are frequently obtained first, and that these subse-
`quently transform to stable forms.
`Eventually, either at the tirst scale-up site or when the process is
`moved to a new site, the thermodynamically preferred form will appear.
`
`Lupin Ex. 1043 (Page 5 of 33)
`
`
`
`334
`
`Brittain and Fiese
`
`When this change occurs late in development, retesting of the substance
`is required, to correct the analytical profile of the compound, a,s well
`as expensive clinical or toxicology testing. In the competitive environ-
`ment of today, time is money, and delaying an NDA can be as cosily
`as the expense of additional clinical or toxieological testing. It is the
`appearance of a thermodynamically preferred polymorph late in the
`development cycle that often requires the use of seed crystals during
`processing. One occasionally runs into legends of "whiffle dust," or
`seed crystals circulating in the air-handling system, which lead to the
`occurrence of the disappearing polymorphs discussed earlier in Chap-
`ter I. Experienced process chemists who have tried to generate an un-
`stable polymorph for an analytical standard generally support the ten-
`ets of this legend and contribute to its dissemination.
`
`III. EFFECTS OF PARTICLE SIZE REDUCTION
`
`The last processing step in the production of bulk drug substances usu-
`ally involves milling to reduce the particle size distribution of the mate-
`rial. This is ordinarily conducted using the mildest conditions possible
`to render a sample homogeneous, or through the use of more rigorous
`milling to reduce the primary particle size in an effort to improve for-
`mulation homogeneity or dissolution and bioavailability. In the latter
`process, a substantial amount of energy is used to process the substance,
`which can result either in a polymorphic conversion or in the generation
`of an amorphous substance. The formation of an amorphous material
`is highly undesirable, since it will often be hygroscopic and more water
`soluble than any of the crystalline forms. The amorphous material must
`also be considered as being a thermodynamically metastable state of
`high energy, and a variety of pathways exist that can result in a back-
`conversion to a crystalline form of the material. This will certainly alter
`the dissolution characteristics and possibly even the bioavailability of
`the drug. In any case, the use of any rigorous milling process requires
`careful analysis for consequent changes in crystailinity or crystal form.
`Hancock and Zografi have reviewed the characteristics of the
`amorphous state and methods whereby this form of a given material
`may be obtained [4], and this information is also covered in the final
`chapter of this book. Amorphous materials are disordered, have the
`
`Lupin Ex. 1043 (Page 6 of 33)
`
`
`
`Effects of Pharmaceutical Processing
`
`335
`
`highest free energy content, have the highest water solubility, and are
`usually hygroscopic. The effect of amorphous materials or amorphous
`regions within pharmaceutical solids is to convert the normal solid
`properties of high elasticity and brittleness to varying degrees of visco-
`elasticity that allow the materials to flow under the mechanical stress of
`milling or t,3bleting. Upon heating, amorphous materials pass through a
`glass transition temperature and convert to a crystalline state. The effect
`of adsorbed moisture from the atmosphere or excipients is to act as a
`plasticizer, lowering the glass transition temperature, increasing molec-
`ular mobility in the.solid, and allowing crystallization to occur at a
`lower temperature. Thus any rigorous milling of a drug substance re-
`quires careful analysis and monitoring for subsequent changes in crys-
`tailinity.
`Much of the literature on the milling of polymorphs involves long
`grinding or ball-milling times, which impart unusual thermodynamic
`sn-ess to the material and possibly lead to confusion about the real ef-
`fects of milling on polymorphism. In practice, drugs are typically
`milled in a Bantam Mill or a Fitzpatrick Mill (alone or with excipients)
`where the exposure time of the material to stress is very short. One
`would predict that the thermodynamic impact would be very small, and
`therefore one might expccl to observe little or no change in polymor-
`phism arising from effects of industrial-scale milling.
`Nevertheless, one can glean an understanding as to the effect of
`milling on polymorphism from ball-nfilling studies, such as those con-
`ducled by Miyamae et al. on (E)-6-(3,4-dimethoxy-phenyl)-I-ethyl-4-
`mesitylimino-3-methyl-3,4-dihydro-2(1H)-pyrimidinone [5]. In this
`work, the title compound was milled for up to 60 rain and then stored
`at ambient conditions for up to 2 months. It was found that the unstable
`Form A (melting point 118°C) was converted to a noncrystalline solid
`as a result of the milling process but then cryslallized upon storage to
`the stable Form B (melting point 141°C).
`Fostedil exists in two polymorphic forms, characterized by melt-
`ing points of 95.3°C (Form I) and 96.4°C (Form 11), a free energy
`difference of only 71,8 cal/mol at 37°C, and distinctly different infrared
`absorption and x-ray powder diffraction patterns [6]. Solubility studies
`suggested that Form I was more stable than Form II. Mechanical mix-
`ing in an automated mortar showed that complete conversion of Form
`II to Form I occurred in 2 h. Milling fostedil in an industrial fluid energy
`
`Lupin Ex. 1043 (Page 7 of 33)
`
`
`
`336
`
`Brittain and Fiese
`
`mill and a hammer mill resulted in a similar conversion of Form II to
`Form I, presumably through the generation of nuclei on the surface of
`the crystal. The hammer milled material was exposed to less energy,
`which resulted in fewer seed nuclei and therefore less conversion to
`Form I even when exposed to elevated temperature and humidity. In
`contrast, since the fluidized energy mill provides more energy, its use
`generated more surface defect nuclei and greater conversion to the
`Form I polymorph. The presence of excipients also was found to exert
`a strong perturbation on the kinetics of the phase transformation. As
`illustrated in Fig. 1, the presence of microcrystalline cellulose retarded
`the conversion of Form II into Form I with grinding.
`Chloramphenicol palmitate Form B was found to transform to the
`less therapeutically desirable Form A during grinding [7]. The transfor-
`mation could be accelerateat by the presence of appropriate seed crys-
`tals, and it was also found that the least stable Form C could be progres-
`sively converted from Form B and then to Form A if the grinding times
`were sufftcienfly long. In another study, it was shown that the tempera-
`ture increases that accompanied the grinding process could accelerate
`
`100.
`
`,.--. 75-
`
`so.
`
`0
`o.o
`
`Fig. 1. Effect of grinding time on the Form-ll-to-Form-1 phase transforma-
`tion composition of pure fostedil (©). and also for fostedil/microcrystalline
`cellulose mixtures having ratios of 3:1 (,&), 1:1 (’If’), and 1:3 (.e). (The figure
`is adapted from data presented in Ref. 6.)
`
`Lupin Ex. 1043 (Page 8 of 33)
`
`
`
`Effects of Pharmaceutical Processing
`
`337
`
`the phase conversion [81. In fact, when one grinds chloramphenicol
`stearate for a sufficiently long period of time, Form III first turns into
`Form I, and ultimately into an amorphous state [9]. One interesting
`note of flais latter study was the finding that the rate of phase conversion
`was accelerated by the presence of microcrystalline cellulose,
`Clearly, the temperature maintained during the milling process
`can influence the degree of any polymorphic transitions. The ~-and T-
`forms of indomethacin could be converted to an amorphous solid dur-
`ing grinding at 4°(2, but at 30°(2 the T-form converted to the (x-form,
`which could not be further transformed [ 10,1 I]. The authors concluded
`that although the noncrystalline form was stable at 4°C, it evidently
`was unstable with respect to crystallization at 30°C, An illustration of
`the crystal form present in samples of indomethacin as a f-unction of
`grinding time is provided in Fig. 2.
`The transformation behavior of phe,ylbutazone polymorphs dur-
`ing grinding at 4 and 35°(2, and the solid-state stability and dissolution
`behavior of the ground materials, was investigated [121. The ~ I~, and
`~i forms were transformed to the new g-form, which in mrn was trans-
`formed to the t-form (which was stable at 4°(2). On the other hand,
`
`100"
`
`75-
`
`50"
`
`4 5 6 7 6 9 10
`
`Time (bout’s)
`
`Fig. 2. Effect of grinding time (conducted at 30"C) on the phase composi-
`tion of ¥-indomethaein (©), showing also the s-phase (,) formed. (The figure
`i~ adapted from data presented in Ref. i1.)
`
`Lupin Ex. 1043 (Page 9 of 33)
`
`
`
`338
`
`Brittaln and Fiese
`
`during grinding at 35°C, the g-form was not changed, while the a-form
`was transformed to the ~-form by way of the k-form. The !-form was
`apparently transformed directly to the 15-form. Once obtained by grind-
`ing, the t-form was transformed to the 15-form under 0% relative humid-
`ity at various storage temperalures aftcr an induction time of a few
`hours.
`A common occurrence during grinding is the formation of an
`amorphous, noncrystalline phase. For instance, the grinding of cepha-
`lexin has been found to decrease the degree of crystallinity [13] as well
`as a wide range of physical properties that depend on the crystalline
`content of the material [14]. When the malerial becomes less crystal-
`line, its stability decreases, and the hydrate forms become easier to
`dehydrate. Similar conclusions were reached with respect to the
`strength of the crystal lattice when the effect of grinding on the stability
`of cefixime trihydrate was studied [ 15]. The degree of interaction be-
`tween the waters of hydration and the cefixime molecules was weak-
`ened by grinding, negatively affecting the solid-state stability.
`Four modifications of cimetidine were prepared as phase-pure
`materials, and each was found to be stable dudng dry storage [16]. The
`milling process enabled the conversions of Forms B and C to Form A,
`while Form A transformed into Form D only upon nucleation. In all
`cases, the particle size reduction step resulted in substantial formation
`of the amorphous phase. Compression of the various forms into com-
`pacts did not yield any evidence for phase conversion.
`The pitfalls that can accompany the development of the amor-
`phous form of a drug substance were shown for the capsule formulation
`of (3R,4S)- 1,4-bis(4-methoxy-phenyl)-3-(3-phenylpropyl)-2-azetidi-
`none [I 7]. A. variety of spectroscopic techniques were used to study
`the amorphous-to-crystalline phase transition, and it was determined
`that problems encountered with dissolution rates could be related to
`the amount of crystalline material generated in the formulation.
`One general finding of milling studies conducted on hydrate spe-
`cies is that the grinding process serves to lower the dehydration temper-
`atures of ground malerials, facilitating the removal of lattice water and
`formation of an amorphous product. This behavior has been noted for
`cephalexin [ 13,14], cefixime l 15], cyclophosphamide [ 18], 2-[(2-meth-
`ylimidazoyl- l-yl)-methyl]-benzolJ]thiochrornen- 1-one [ 19], and lacti-
`tol [20], to name a few representative examples.
`
`Lupin Ex. 1043 (Page 10 of 33)
`
`
`
`Effects of Pharmaceutical Processing
`
`339
`
`¯ -- 75-
`
`Time (hour~)
`
`Fig. 3. Changes in (x-form content for the (x-monohydrate (I), (x-anhydrate
`(Q), and ~-anhydrate (O) mo(fificafions of lactose with grading l~me. (The
`figure is adapted from data pm~ented in Ref. 22.)
`
`Although most studies have been concerned with the state of the
`drug entity in either bulk or dosage form, milling can also affect the
`crystalline state of excipients. For example, isomerization was found
`to take place during the grinding of the o.-monohydrate, ot-anhydrale,
`and i]-anhydrate forms of lactose [21]. The crystalline materials were
`all transformed into amorphous phases upon grinding, but these materi-
`als quickly re-sorbed water to approach the equilibrium composition
`ordinarily obtained in aqueous solutions. This behavior has been illus-
`traled in Fig. 3. In a subsequent study [22], these workers determined
`the degree of crystallinity during various stages of the grinding process
`and concluded that while the isomerization rate of the ot-monohydrate
`phase depended on the crystallinily, the rates tbr the two anhydrale
`phascs depended on the content of absorbed water.
`
`IV. EFFECTS DUE TO GRANULATION
`
`When the requircments of a given formulation require a granulation
`step, this will represent an opportunity for a change in crystal form of
`
`Lupin Ex. 1043 (Page 11 of 33)
`
`
`
`340
`
`Brittaln and Fiese
`
`the drug to take place, The problem will be most acute when a wet
`granulation step is used, since a potential transforming solvent is added
`to the blend of drug and excipients. The mixture is physically processed
`in the wet stage until homogeneity is obtained and then dried at a fairly
`significant temperature. The rationale for including a granulation step
`is to improve flow and blend homogeneity, permitting the high-speed
`compression of tablets. The granulation process is used to maintain the
`distribution of the drug throughout the formulation even during free
`flow, thus blend homogeneity.
`Clearly, one can consider a wet granulation to be equivalent to a
`suspension of the drug entity in a mixture of solvent and excipients.
`Since the usual solvent is water, one can encounter a variety of inter-
`conversions between anhydrates and hydrates, or between hydrates and
`hydrates, which are mediated by the presence of the solvent. It is
`equally clear that one should not expect to be able to wet-granulate the
`metastable phase of a particular compound if that metastable phase is
`capable of transforming into a more stable form. A discussion of sol-
`vent-mediated phase transformations has been given in an earlier chap-
`ter and need not be repeated here.
`It has been noted that ehlorpromazine hydroehloride Form II ex-
`hibits severe lamination and capping when compressed, and that.wet
`granulation with ethanol and water significantly improves the tableting
`characteristics [23]. The reason for this process advantage was shown
`to entail a phase change of the initial Form II to the more stable Folm
`I during the granulation step. It was concluded that the improvements
`in tabletability and tablet strength that followed the use of wet granula-
`tion were duc to changes in lattice structure that facilitated interpartieu-
`late bonding on rcompaction.
`The effects of granulation solvent on the bulk properties of gran-
`ules prepared using different polymorphic forms of carbamazepine
`have been studied I24]. It was found that although the anhydrate phase
`of the drug transformed to the dihydrate phase in the presence of 50%
`aqueous ethanol, the phase transformation did not take place when ei-
`ther pure water or pure ethanol was used as the granulating solution.
`This unusual finding was attributed to the fact that the solubility of the
`drug in 50% ethanol was 37 times higher than that in pure water. Gran-
`ules processed using 50% ethanol were harder than those processed
`with pure solvents and led to the production of superior tablets. This
`
`Lupin Ex. 1043 (Page 12 of 33)
`
`
`
`Effects of Pharmaceutical Processing
`
`341
`
`work demonstrates the extreme need to evaluate the robustness of the
`granulation step during process development.
`The crystal characteristics of a drug substance can undergo a se-
`quence of reactions during wet granulation and subsequent processing.
`When subjected to a wet granulation step where 22% w/w water was
`added to dry solids, and the resulting mass dried at 55°C, an amorphous
`form 0f (S)-4-[[[1-(4-fluorophenyl)-3-(l -methylethyl)-lH-indol-2-yll-
`ethynyl]-hydroxyphosphinyl]-3]-hydroxybutanoic acid, disodium salt,
`was obtained [251. However, this amorphous gradually became crystal-
`line upon exposure to humidity conditions between 33 and 75% RH.
`Depending on the exact value of the applied humidity, different hy-
`drates of the drug substance could be obtained in the formulation.
`
`V. EFFECTS DUE TO DRYING
`
`Whenever a wet suspension containing a drug substance is dried, the
`possibility exists that a change in crystal state will take place. It has
`been amply shown in earlier chapters that anhydrates or amorphates
`can be produced by the simple desolvation of a solvate species, and
`such reactions are always possible during any drying step. The produc-
`tion of anhydrate phases by simple drying is one example of a reaction
`that can accompany the drying process, and this reaction type has been
`fully discussed in an earlier chapter.
`In the simplest type of drying procedure, moist material from the
`wet granulation step is placed in coated trays and the trays are placed
`in drying cabinets with a circulating air current and thermostatic heat
`control. Historically, the tray drying method was the most widely used
`method, but more recently, fluid-bed drying is now widdy used. In
`drying tablet granulations by fluidization, the material is suspended and
`agitated in a warm air stream. The chief advantages of the fluid-bed
`approach are the speed of drying and the degree of control that can be
`exerted over the process. The wet granulations are not dried to zero
`moisture; for a variety of reasons one seeks to maintain a residual
`amount of moisture in the granulation. It is evident from these simple
`considerations that the combination of solvent and drying conditions
`provides a suitable environment for the generation of new polymorphs
`or solvates when such conversion mutes are available.
`
`Lupin Ex. 1043 (Page 13 of 33)
`
`
`
`342
`
`Brittain and Fiese
`
`During ordinary manufacturing processes, crystals of the drug
`substance are dried under vacuum or through the circulation of warm
`dry air. Evaluation of wet and dried samples of the bulk substance by
`thermogravimetric analysis and hygroscopicity studies usually yields
`the necessary insight into the limiting parameters of the drying process.
`Since drying times can be relatively long and the environmental tem-
`perature mild (such as 24 to 48 h at 60°C), partial or total polymorphic
`conversion is possible. The likelihood that phase conversion will take
`place becomes increasingly less as the solvent is removed during dry-
`ing. This area has been thoroughly covered earlier in Chapter 5, so
`only a few illustrative examples will be quoted at this time.
`Shefter et at. used x-ray diffraction analysis to show that over-
`drying ampicillin trihydrate resulted in an unstable amorphous product,
`and that the drying of theophylline hydrate yielded a crystalline anhy-
`drous form [26]. Kitamura et al. dehydrated (with vacuum) cefixime
`trihydrate to obtain a crystalline anhydrous form, which also proved
`to be unstable [27].
`Otsuka et al. studied the effect of humidity and drying on the
`polymorphic transformation rate at 45°C for six forms of phenobarbital
`[28]. Figure 4 shows that the monohydrate (Form C) and the hemihy-
`drate (Form E) slowly convert to the anhydrous Form B under high-
`hnmidity stress conditions (45°C and 75% RH), while the conversion
`is very fast at low humidity (45°C and 0% RH). This is reasonable,
`since the driving force to form anhydrous material is a dry environment.
`The key point of Figure 4 is the rapid conversion of phenobarbitol in
`less than t2 at 45°C and 0% RH, which represents very reasonable
`processing conditions for an industrial drying oven.
`The sodium salt of 3-(((3-(2-(7-chloro-2- quinolinyl)ethenyI)phe-
`nyl)((3-dimethylamino)-3-oxo-propyl)thio)propanoic acid represents
`an unusual case of a hygroscopic drug substance, where the surface-
`active substance (in both crystalline and lyophilized forms) produced
`nonflowing, semisolid masses with exposure to increasing relative hu-
`midity [29]. The substancc was shown to form first an amorphous mate-
`rial and then a mesomorphic phase, as die moisture sorption increased
`with exposure to relative humidity.
`The favorite endpoint of the process chemist is to "dry to constant
`weight," but this laudable goal can lead to the production of a desoI-
`
`Lupin Ex. 1043 (Page 14 of 33)
`
`
`
`Effects of Pharmaceutical Processing
`
`Time (days)
`
`Fig. 4. Jander plots of one polymorphic transformation of phenobarbital,
`Illustrated are data for ~he coaversion at 45°C of Form C (monohydratc phase)
`to Form B (anhydrate phase), The 0% relative humidity atmosphere poinL~
`are given by the open symbols, and the 75% reladve humidity atmosphere
`points are given by the closed symbols, (The figure is adapted from data pre-
`sented in Ref. 28.)
`
`vated product. Without doubt, the overdrying process has produced
`many anhydrous lots of bulk drug substance, which unfortunately are
`eventually found to be unstable.
`Since the effects of simple drying have been more fully discussed
`in detail in Chapter 5 of this book, we will turn to case studies that
`illustrate how the use of two specialized drying methods can lead to
`phase interconversions.
`
`A. Changes in Crystalline Form Accompanying the
`Spray-Drying Process
`
`The spray-drying process first requires the formation of a slurry to be
`sprayed, which can be a concentrated solution of the agent to be dried
`or a dispersion of the agent into a suitable nondissolving mediurn. The
`dispersion is then atomized into droplets, which are exposed to a heated
`atmosphere to el?feet flae drying process. Completion of the process
`yie|ds a dry, freeflowing powder that ordinarily consists of spherical
`
`Lupin Ex. 1043 (Page 15 of 33)
`
`
`
`344
`
`Brlttain and Fiese
`
`particles of relatively uniform particle size distribution. For instance,
`the morphology of spray-dried lactose has been contrasted with that
`of the monohydrate and anhydrous phases of lactose, with significant
`differences being reported [30].
`One interesting feature of spray-drying is the possibility of con-
`trolling the final crystal form through manipulation of the drying condi-
`tions. For instance, three different crystalline forms of phenylbutazone
`were prepared from methylene chloride solution by varying the drying
`temperature of the atomized droplets between 30 and 120°C [31]. One
`of the isolated polymorphs could not be obtained by any crystallization
`procedure and could only be produced using extremely slow solvent
`evaporation rates.
`Using phenol?artitone and hydroflumethiazide as examples, it has
`been shown that high-energy solids can be produeed through the use
`of spray-drying [32]. Commercially available phenobartitone is ob-
`tained as Form II, but with spray-drying the authors were able to obtain
`Form II1 having a large specific surface area. The analogous spray-
`drying of hydroflumethiazide yielded an amorphous solid. The spray
`drying of indomethacin produced a viscous glassy phase, which was
`found to be physically unstable with time [331. Upon storage, the glassy
`solid convened into a mixture of crystalline Forms I and II, Representa-
`tive x-ray powder diffraction pattcrns of these materials are shown in
`Fig. 5.
`Spray-drying is often used to encapsulale drug substances into
`excipient matrices, but phase intercon~,ersions are still possible in such
`situations. Sulfamethoxazole Form I was microencapsulated with cellu-
`lose acetate phthalate and lalc, colloidal silica, or montmorillonite clay
`by a spray-drying technique, and the drug was found to convert to Form
`1I during the process [34]. Increasing the amount of cellulose acetate
`phthalale in the formulation led to increased amorphous drug content,
`but increasing the talc level yielded more polymorphic conversion. In
`a subsequent study, the authors showed that no phase conversion took
`place in formulations containing colloidal silica [35].
`Frequently, the spray drying proces~ yields amorphous materials,
`which undergo crystallization upon storage or exposure to suitable en-
`vironmental conditions. The effect of various additives on the recrystal-
`iization of amorphous spray-dried lactose has been studicd [36]. The
`
`Lupin Ex. 1043 (Page 16 of 33)
`
`
`
`Effects of Pharmaceutical Processing
`
`345
`
`Scattering Angl~ (deg. 2-6)
`
`Fig. 5. X-ray powder diffraction patterns for (A) crystalline indomethacin,
`(B) spray-dri~ indomcthacin, and (C) indolnethaein spray-dried with :5%
`polyvinylpyrrolidone and stored for two months. (’The figure is adapted from
`data presented in Ref. 32.)
`
`presence of magnesium stearate was found to inhibit the recrystalliza-
`tion process, while layers of microcrystalline cellulose in the spray-
`dried producls could result in long lag times prior io recrystallization.
`It was deduced that the onset of crystallization was critically related
`to the mobility of water in the formulations.
`
`B. Changes in the Crystalline State of Lyophilized
`Products
`
`Another drying procedure that can yield changes in drug crystal form
`is Ihat of freeze-drying, or lyophilization. In this approach, the material
`
`Lupin Ex. 1043 (Page 17 of 33)
`
`
`
`346
`
`Brittain and Fiese
`
`to be dried is prepared as an aqueous solution or suspension and then
`frozen rapidly and cooled to a temperature below its eutectic point.
`The frozen formulation is then exposed to vacuum and the ice removed
`by sublimation, Since lyophilized products are often dried to moisture
`levels less than 1%, the materials are ordinarily hygroscopic and must
`be protected from adventitious water to prevent any unwanted phase
`transformation steps. In usual practice, the product is produced in its
`amorphous state, which is favorable for its subsequent solubilization
`at the time of its intended use. Consequently, the study of any possible
`moisture-induced crystallization is important to the characterization of
`a lyophilized product.
`The effect of storage conditions on the crystalline nature of lyoph-
`ilized ethacrynate dodium has been reported [37]. Samples of the drug
`substance were dried to various moisture levels and then stored at either
`60°C or 30°C/75% RH. It was found that crystalline drug substance
`was obtained after short periods of time as long as sufficient levels of
`water were either present in the initial lyophilized solid or introduced
`by adsorption of humidity. The crystalline form of the drug was identi-
`fied as a monohydrate phase.
`Cefazolin sodium is capable of existing in a number of crystalline
`modifications, but the amorphous state is produced by the lyophiIiza-
`tion process 138]. The amorphous form retained its nature at relative